Background: Hepatocellular carcinoma (HCC) is the end-stage of chronic liver diseases (CLDs). The main aetiologies of CLDs are chronic hepatitis C virus (HCV) infection. Objective: The aim of this work was to evaluate diagnostic value of TGF-β1 in patients with liver Fibrosis and HCC. Materials and Methods: In the present study, we have investigated 51 patients with Fibrosis (F2-F4), 30 (HCC) patients, in addition 40 normal healthy individuals were enrolled in this study as control group. Laboratory liver fibrosis indices including FIB-4 ratio, APRI ratio, and AST/ALT ratio were calculated in all studied groups. AFP and carcinoembryonic antigen (CEA) were estimated in all studied groups. TGF-β1 was evaluated using Flow Cytometry technique. Results: There was high significance difference in APRI, FIB-4 between HCC, Fibrosis patients comparing with Control group (p<0.05), also there was high prevalence TGF-β1 in HCC patients comparing with both Fibrosis and healthy control group (P<0.005). Conclusion: TGF-β1 has diagnostic value in assessment of hepatocellular carcinoma.